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Abstract
Background: Snakebite is a global health issue and treatment with antivenom continues to be problematic. Brown snakes
(genus Pseudonaja) are the most medically important group of Australian snakes and there is controversy over the dose of
brown snake antivenom. We aimed to investigate the clinical and laboratory features of definite brown snake (Pseudonaja
spp.) envenoming, and determine the dose of antivenom required.
Methods and Finding: This was a prospective observational study of definite brown snake envenoming from the Australian
Snakebite Project (ASP) based on snake identification or specific enzyme immunoassay for Pseudonaja venom. From January
2004 to January 2012 there were 149 definite brown snake bites [median age 42y (2–81y); 100 males]. Systemic envenoming
occurred in 136 (88%) cases. All envenomed patients developed venom induced consumption coagulopathy (VICC), with
complete VICC in 109 (80%) and partial VICC in 27 (20%). Systemic symptoms occurred in 61 (45%) and mild neurotoxicity in
2 (1%). Myotoxicity did not occur. Severe envenoming occurred in 51 patients (38%) and was characterised by collapse or
hypotension (37), thrombotic microangiopathy (15), major haemorrhage (5), cardiac arrest (7) and death (6). The median
peak venom concentration in 118 envenomed patients was 1.6 ng/mL (Range: 0.15–210 ng/mL). The median initial
antivenom dose was 2 vials (Range: 1–40) in 128 patients receiving antivenom. There was no difference in INR recovery or
clinical outcome between patients receiving one or more than one vial of antivenom. Free venom was not detected in 112/
115 patients post-antivenom with only low concentrations (0.4 to 0.9 ng/ml) in three patients.
Conclusions: Envenoming by brown snakes causes VICC and over a third of patients had serious complications including
major haemorrhage, collapse and microangiopathy. The results of this study support accumulating evidence that giving
more than one vial of antivenom is unnecessary in brown snake envenoming.
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Introduction
Snake envenoming is a major problem in many parts of the
world. [1] It has been estimated that there are over 440,000 snake
envenomings and 20,000 deaths every year. [2] Although
antivenom is the major treatment for snake bite there are ongoing
issues with the effectiveness and dose of antivenom, and deaths
continue to occur despite antivenom and good supportive care,
even in developed countries. [3].
The widely distributed elapid genus of brown snakes (Pseudonaja
spp.) (Figure 1) accounts for the majority of cases of severe
envenoming and deaths from snakebite in Australia. [4] The
correct dose of brown snake antivenom has been the subject of
considerable debate and change over time. Antivenom is
expensive and has a limited shelf life making it difficult for rural
hospitals to maintain adequate supplies, particularly if large doses
are being recommended. [5] Antivenom also has the potential for
anaphylactic reactions [6] and serum sickness making it important
to balance treatment benefit with the risk of adverse reactions.
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Brown Snake Antivenom has been available from CSL Ltd.
since 1956 and one vial (1000 Units) is aimed at neutralising the
average yield of venom from one milking of an eastern brown
snake (Pseudonaja textilis); one unit (1 U) of antivenom is defined as
the amount required to neutralise 0.01 mg of dried venom [7,8].
This dose is therefore expected to cover the most extreme
theoretical possibility that the venom yield on milking is
completely injected by the snake bite (i.e. the venom glands are
almost completely emptied and no venom is left on the skin) and
this amount is completely absorbed (i.e. none is inactivated locally
in the tissues mast cell and macrophage responses). However,
measurement of venom concentrations in vivo provide a better
estimate of the actual venom load in human bite cases. Recent
studies in Australian snakebite have found venom concentrations
in patients that suggest a much smaller typical venom load and
that usually only a small proportion of the venom reaches the
central circulation. [9,10].
Although it is well known that the main feature of brown snake
envenoming is venom induced consumption coagulopathy
(VICC), [11,12,13] less common clinical effects are not well
defined. [14] Major haemorrhage causing death has received
widespread publicity, and early collapse and cardiac arrest also
appear to be an important cause of death from brown snake
envenoming. [15,16].
Here we report a large series of proven brown snake
envenoming cases to better describe the clinical syndrome of
brown snake envenoming and to determine whether one vial of
brown snake antivenom is sufficient to treat brown snake
envenoming.
Methods
This study was part of the Australian snakebite project (ASP)
which prospectively recruits suspected and definite snake bite
patients from more than one hundred hospitals across Australia
and referrals from all major Australian poison centres. We
reviewed all cases of definite brown snake envenoming. The
recruitment, design and data collection have been described
previously. [6,17] Approval was obtained from several Human
Research and Ethics Committees to cover all involved institutions.
Patient demographics, laboratory results, clinical effects, treat-
ments and outcomes are all documented as part of ASP onto our
case report forms that are faxed by the treating doctor to the study
coordinating centre where the data is entered into a relational
database. Where possible, patient serum is collected pre and post
antivenom administration, centrifuged, and stored at 280uC for
venom concentration quantification.
Patients were included in this study if the snake was identified by
an expert or if brown snake venom was detected in the serum. All
cases recruited to ASP between January 2004 and January 2012
were reviewed if they were identified as possible brown snake bites
or envenoming cases based on expert snake identification, positive
snake venom detection kit (sVDK) for brown snake venom, or
clinical suspicion. Cases of VICC positive for tiger snake or taipan
venom on sVDK on bite site or urine, but found to be negative in
the serum for either venom were then tested with formal venom-
specific enzyme immunoassay (EIA) for brown snake, and included
if positive. The sVDK was not used as an inclusion criterion in the
absence of expert snake identification or brown snake venom
detected with venom-specific enzyme immunoassay.
Cases were classified into envenomation syndromes: VICC
(complete or partial), myotoxicity, thrombotic microangiopathy
and systemic symptoms, as previously described. [17] Complete
VICC is defined as undetectable fibrinogen and/or raised D-
Dimer (at least 10 times the assay cut-off or .2.5 mg/L) and an
international normalised ratio (INR) .3. Partial VICC is defined
as low but detectable fibrinogen, elevated D-Dimer and a
maximum INR ,3. Other defined clinical effects were haemor-
rhage (type of haemorrhage; major haemorrhage was defined as
an intracranial haemorrhage, large gastrointestinal haemorrhage
with a drop in haemoglobin or any other life-threatening
haemorrhage), early hypotensive collapse, cardiac arrest, seizure,
electrocardiogram (ECG) changes and troponin concentrations.
Treatment, complications and adverse events were analysed,
Figure 1. Brown snake (Pseudonaja textilis). Photo taken by
Gunther Schmida.
doi:10.1371/journal.pone.0053188.g001
Table 1. Demographic features of 136 definite brown snake
envenoming cases.
Age [yr] (median, range) 42; (2–81)
Sex (Male) 100 74%
State/Territory
VIC 1 1%
WA 42 31%
QLD 52 38%
NSW 30 22%
SA 1 1%
NT 10 7%
Bite site
Upper Limb 55 40%
Lower Limb 81 60%
PBI 121 89%
Antivenom 128 94%
Snake Handler 10 7%
Alcohol involved 8 6%
Activity*
Gardening/outdoor work 40 29%
Intentionally interacting with snake 41 30%
Bush/walking/playing 45 33%
Indoors 8 6%
Other 1 1%
*not known in one case.
doi:10.1371/journal.pone.0053188.t001
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including systemic hypersensitivity reactions to antivenom, which
were defined as anaphylaxis if they met NIAID/FAAN consensus
criteria for this diagnosis, [18] and defined as severe according to
the grading system developed by Brown. [19].
Bite locations were converted into latitude and longitude
coordinates using http://www.csu.edu.au/australia/latlong/
index.html, to plot a distribution map. In line with recent
taxonomic revisions, [20] cases were divided into Pseudonaja
species groupings based on non-overlapping geographical regions:
P. textilis (Eastern Australia); P. nuchalis (‘Top End’, Northern
Territory) and ‘Western Australia’ including P. modesta, P. mengdeni
and P. affinis. Locations outside these regions or where there was
significant overlap were not included in this sub-group analysis.
All antivenom used in the study was equine F(ab’)2 and was
manufactured by CSL Ltd. The dose of antivenom is defined as
the amount administered before the first available post-antivenom
blood sample for venom-specific enzyme immunoassay. Polyvalent
antivenom contains on average the equivalent of eight vials of
brown snake antivenom, based on a study of CSL terrestrial snake
antivenoms. [21] In patients given polyvalent antivenom the dose
was converted to the equivalent number of brown snake
antivenom vials using this 8 to 1 conversion. The total dose was
also calculated for each patient receiving further antivenom.
Methods for the enzyme immunoassay have previously been
described. [10] Polyclonal antibodies (IgG) to brown snake venom
raised in rabbits are used, with detection by biotinylated antibodies
and streptavidin horseradish peroxidase. The limit of detection for
brown snake venom was 0.15 ng/ml. The peak pre-antivenom
venom concentration is reported where available. An enzyme
immunoassay using labelled anti-Horse IgG was also used to
detect antivenom in patient serum to confirm antivenom
administration.
Medians, interquartile ranges (IQR) and ranges are used to
report continuous data, and proportions were reported with 95%
confidence intervals (CIs). For the enzyme immunoassay standard
curves were fitted by linear and non-linear regression using both
Excel and Prism 5.03 for Windows [GraphPad Software, San
Diego California USA, www.graphpad.com].
Results
There were 226 possible brown snake bites recruited to ASP
and 149 of these were definite brown snake bites by our definition
and included in our analysis, 13 of which were non-envenomed.
Of the excluded patients, 73 patients had no pre-antivenom serum
available for testing and four patients had no brown snake venom
detected but had either Notechis sp. or Tropidechis carinatus venom
detected. The snake was identified in 20 of the 136 envenomed
patients.
Demographics of the 136 patients with definite brown snake
envenoming are summarised in Table 1. The median patient age
was 42 years (IQR: 25 to 53, Range: 2 to 81) and the majority
were male (100; 74%). The distribution of bite locations is shown
in Figure 2. Most bites occurred in Queensland, Western Australia
and New South Wales with only one case in Victoria. Most
patients were bitten while undertaking yard work or gardening
(40), when walking or in the bush (44), or intentionally interacting
with the snake (41); only eight patients were bitten indoors.
Figure 2. Distribution of definite brown snake bites including envenomed patients (+) and non-envenomed patients(N).
doi:10.1371/journal.pone.0053188.g002
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The clinical effects of the 136 envenomed patients are
summarised in Table 2. VICC occurred in all patients, systemic
symptoms in 61 patients (45%), mild neurotoxicity in only two
patients (2%) and myotoxicity in none. There were six deaths, five
of which occurred following an early cardiac arrest and subsequent
multi-organ failure/hypoxic injury and one from an intracranial
haemorrhage (Table 3). Severe envenoming occurred in 51 (38%)
of patients which includes collapse/hypotension, seizure, cardiac
arrest, major haemorrhage, thrombotic microangiopathy or death.
The grouping of patients into each clinical syndromes including
the numbers in each group is shown in Figure 3. Local effects were
minor in all cases, with local pain in 70 (51%) and fang marks in
98 (72%).
Complete VICC developed in 109 patients (80%) and partial
VICC in 27 (20%). The median time to recovery of complete
VICC to an INR of less than 2 was 15.5 hours (IQR: 11.5 to
19.4 hr; n= 105). Three patients died with an INR greater than 2
and one patient was discharged with an INR of 3.1. The median
time from complete VICC to a normal INR (,1.3) was 23.3 hours
(IQR: 18.3 to 37.3 hr; n = 83). Twenty two patients were
discharged with an INR of 1.3 or greater. Major haemorrhage
occurred in five cases, three gastrointestinal haemorrhages and
two intracranial haemorrhages both associated with hypertension.
Table 4 provides a comparison between patients with VICC and
partial VICC which shows that more severe effects occurred in
patients with complete VICC except thrombotic microangiopathy
which occurred with similar frequency in partial VICC.
Early collapse and/or hypotension occurred in 37 patients. In
19 patients with a known time of collapse this occurred a median
of 30 minutes (range: 2 to 90 min) after the bite. Cardiac arrest
occurred in seven patients with collapse and four of these were
fatal. Non-fatal cardiac arrests received prompt cardiopulmonary
resuscitation. Eight patients of the 37 had generalised seizures,
seven of which were hypotensive immediately prior to the seizure.
No ventricular arrhythmias were reported at the time of collapse
or cardiac arrest. Two patients had atrial fibrillation.
ECG and troponins were not routinely done in all patients.
Three patients with early collapse had abnormal electrocardio-
grams (ST segment depression, atrial fibrillation and widespread T
wave inversions). Troponin was measured in only 24 patients; the
median troponin was somewhat higher in the 12 who had
collapsed than the 12 who did not [0.7 mg/L (range: 0.05 to
22.4 mg/L) vs. 0.17 mg/L (0.01 to 2.4 mg/L)].
Fifteen patients (11%) developed thrombotic microangiopathy
with thrombocytopenia and fragmented red blood cells in all 15
cases, acute renal failure with anuria/oliguria in ten cases and an
abnormal creatinine without renal failure in five. One patient
developed acute renal impairment without significant thrombocy-
topenia but had severe environmental hyperthermia. Another nine
patients had an abnormal creatinine without all the features of
thrombotic microangiopathy.
Two patients had mild neurotoxicity. One developed ptosis
prior to having an intracerebral haemorrhage. The second had
unusual and fluctuating neurological findings including ptosis,
Table 2. Clinical features of the 136 patients with definite
brown snake envenoming.
Clinical Syndrome/Effects Number %
VICC
Complete 109 80%
Partial 27 20%
Bleeding
Major haemorrhage 5 4%
Intracranial Haemorrhage 2 1%
Gastrointestinal Haemorrhage 3 2%
Bite site 32 24%
Intravenous cannula site 43 32%
Gum bleeding 19 14%
Neurotoxicity (mild) 2 1%
Myotoxicity 0
Systemic Symptoms
Nausea 71 52%
Vomiting 44 32%
Headache 78 57%
Abdominal Pain 37 27%
Diaphoresis 49 36%
Diarrhoea 11 8%
Cardiovascular Effects
Early collapse/hypotension 37 27%
Cardiac arrest 7 5%
Seizures 8 6%
Thrombotic microangiopathy 15 11%
Acute renal failure 11 8%
Abnormal creatinine 14 10%
doi:10.1371/journal.pone.0053188.t002
Table 3. Details of the six deaths from brown snake envenoming.
Sex/Age Collapse Onset Antivenom Dose Details
M43 minutes 5 vials BSAV Bitten at desk. Early cardiac arrest, CPR by family.
M20 unknown 6 vials BSAV Found unconscious after running; very hot day; hyperthermic
F61 40 minutes 5 vials PVAV Bitten while gardening, chest pain, seizure and asystolic arrest
M16 unknown 5 vials BSAV, 1 vial PVAV Picked up snake in bush. Found collapsed, asystolic, no CPR by bystanders.
F10 minutes 8 vials BSAV, 1 vial PVAV Walking in garden, collapsed, CPR by family
F69 None 5 vials BSAV Severe uncontrolled hypertension for several hours while remaining
coagulopathic, followed by sudden onset of headache then drowsiness 17 hrs
post bite; CT scan: large cerebral haemorrhage
CPR – cardiopulmonary resuscitation; PVAV – polyvalent antivenom; BSAV – brown snake antivenom.
doi:10.1371/journal.pone.0053188.t003
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Table 4. Comparison of the clinical effects between patients with complete VICC and partial VICC.
Clinical Effects Complete VICC (109) % Partial VICC (27) %
Bleeding
Major haemorrhage 5 5% 0
Intracranial Haemorrhage 2 2% 0
Gastrointestinal Haemorrhage 3 3% 0
Bite site 29 27% 3 11%
Intravenous cannula site 40 37% 3 11%
Gum bleeding 18 17% 1 4%
Minor Haemorrhage 48 44% 3 11%
Neurotoxicity (mild) 2 2% 0
Systemic Symptoms 53 49% 8 30%
Other Effects
Early collapse/hypotension 37 34% 0
Acute renal failure 8 7% 3 11%
Abnormal creatinine 9 8% 5 19%
Thrombotic microangiopathy 11 10% 4 15%
Cardiac arrest 7 6% 0
Seizures 8 7% 0
Death 6 6% 0
doi:10.1371/journal.pone.0053188.t004
Figure 3. Number of patients with partial or complete venom induced consumption coagulopathy (VICC), collapse or no collapse,
thrombotic microangiopathy (TMA), major haemorrhage and death.
doi:10.1371/journal.pone.0053188.g003
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lateral gaze diplopia, bulbar weakness, dysphonia and facial
weakness.
Venom concentrations and clinical effects were similar between
the three groupings of brown snakes (Eastern or P. textilis,
Northern and Western; Table 5) except more cases of hypotensive
collapse and cardiac arrest occurred in the eastern group.
Bite site swabs were tested using the sVDK in 117 envenomed
patients and were positive for brown snake venom in 98 (84%),
negative in 18 and inconclusive in one. A urine sVDK was done in
45 patients and was positive for brown snake venom in 40 and
negative in 5.
Pre-treatment serum samples were available in 131 envenomed
cases and eight non-envenomed patients. Venom was not detected
in any of the eight non-envenomed patients. The median peak
venom concentration in the envenomed patients was 1.6 ng/mL
(IQR: 0.6 to 5 ng/mL; range 0.15 to 210 ng/mL). There were no
significant differences in brown snake venom concentrations
between different groups of Pseudonaja sp. There was a significant
difference in peak venom concentrations between patients who
developed complete VICC compared with partial VICC (Table 5).
The median peak concentration in patients developing collapse,
cardiac arrest or death was not notably higher than for other
patients (Table 6).
Antivenom was given in 128 envenomed patients with a median
initial dose of two vials (IQR 2 to 5, Range 1 to 40). Further doses
were given in 25 patients and the total dose in all patients was a
median of two vials (IQR 2 to 5, Range 1 to 40). Twenty five
patients received only one vial of antivenom initially, and five of
these received a second dose of one vial (3), two vials (1) and eight
vials (1). Clinical effects were similar in patients receiving an initial
dose of one vial compared with more than one vial, including the
frequency of collapse. Outcomes were similar between patients
receiving an initial dose or a total dose of one vial and those
receiving greater than one vial, including the time to recovery of
VICC (Figure 4 and Figure 5). The median brown snake venom
concentration of those receiving an initial dose of one vial was not
significantly different to those receiving more than one vial
[0.9 ng/ml (IQR: 0.3 to 5.3 ng/ml) vs. 2 ng/ml (IQR: 0.6 to
5.6 ng/ml; p = 0.26).
Post-treatment samples were available in 115 patients given
antivenom. Free venom was not detected in 112 patients,
including in 16 patients after only one vial of antivenom. Three
patients had low concentrations of venom detected post-anti-
venom (0.4 to 0.9 ng/ml) [Table 5]. Thirty eight of the 73
excluded possible brown snake bites had post-treatment samples
available and free venom was not detected in any, including 12
patients receiving one vial of antivenom.
Eight envenomed patients were not given antivenom, seven had
only partial VICC and one presented late with VICC. The venom
concentrations for 5 of the 8 patients who had serial blood samples
available shows venom concentrations decreasing over 20 to 40
hours (Figure 6).
Four patients had anaphylaxis and 13 had skin-only reactions.
There were no severe cases of anaphylaxis.
Discussion
In this series of over a hundred cases of brown snake
envenoming, VICC occurred in every case and was partial in
20% of cases. Neurotoxicity was mild and rare, and myotoxicity
did not occur. Cardiovascular effects were common with
hypotensive collapse occurring in over a quarter of patients,
although non-fatal and fatal cardiac arrests were uncommon.
Deaths in all but one case were attributed to early pre-hospital
collapse and cardiac arrest. Clinical outcomes following one vial of
antivenom were similar to those found with larger doses and
venom was only detected in three cases following antivenom and
Table 5. Details of the three patients with low venom concentrations after their initial dose of antivenom.
Sex/Age
AV
Dose
Initial venom
concentration
Venom
concentration
post-AV Clinical Outcome
Time to
INR ,2 Comment*
F42 2 48 0.5 VICC with no
complications
39 hr INR 2.7, fibrinogen 0.9 g/L at 26 h post-bite; INR 1.3 at 39 h;
discharged at 41 h with venom still detectable on last tested
sample at 26 h.
M39 1 9.7 0.9 VICC with moderate
thrombocytopenia
28 hr INR.12 at 21 h; given 3 units FFP at 24 h; INR 1.5 at 28 h; INR
1.1 at 50 h; discharged at 72 h
M70 1 8.3 0.4 VICC with no
complications
28 hr INR 4.2 at 17 h; INR 1.4 at 27 h; discharged at 36 h with
venom still detectable (0.4 ng/mL) and INR 1.1
AV – antivenom; FFP – fresh frozen plasma;
*All times are post-bite.
doi:10.1371/journal.pone.0053188.t005
Table 6. Comparison venom concentrations for different
clinical effects/severity and different Pseudonaja species
groupings.
Number
Venom Concentration
(Median, IQR) p value
All Cases 131 1.6 (0.5–5)
Coagulopathy
VICC 105 2 (0.5–6.2) 0.0031
Partial VICC 26 0.8 (0.3–1.9) -
Cardiovascular
Collapse 33 3 (0.45–7.7) 0.152
Cardiac Arrest 6 2.3 (0.9–43) 0.552
Death 5 3 (1.4–80) 0.252
Snake Group
Eastern 76 1.3 (0.5–5.5) 0.933
Western 41 1.8 (0.6–4.9) -
Northern 10 1.8 (0.4–2.5) -
1compared to partial VICC (Mann-Whitney);
2compared to all others (Mann-Whitney);
3comparing the 3 groups (Kruskal-Wallis).
doi:10.1371/journal.pone.0053188.t006
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these concentrations were very low and the coagulopathy was
improving (Table 5).
The study emphasizes the importance of cardiovascular effects
in brown snake envenoming. Although these effects are well
recognised in brown snake envenoming the frequency and severity
have not been well quantified in the past. Five of six deaths were a
result of an early pre-hospital cardiac arrest/collapse which is
unlikely to be treatable with antivenom. A recent animal study
suggests that the collapse in Australasian elapids is a result of
hypotension following vasodilation due to the release of endoge-
nous mediators, and is not cardiac in origin. [22].
Unfortunately ECGs and troponins were not routinely col-
lected, but there were moderately elevated troponins in patients
with collapse, and these appeared generally higher than those seen
in patients who did not have a collapse. Further detailed
investigation of patients with and without collapse is required to
Figure 4. Time to recovery of VICC to an INR ,2 comparing patients receiving and initial antivenom dose of one vial (N=18, blue
line), two vials (N=43, green line), or three or more vials (N=43, red line).
doi:10.1371/journal.pone.0053188.g004
Figure 5. Time to recovery of VICC to an INR ,2 comparing patients receiving a total antivenom dose of one vial (N=15, blue line),
two vials (N=38, green line), or three or more vials (N=51, red line).
doi:10.1371/journal.pone.0053188.g005
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determine if the elevated troponin is secondary to the collapse,
rather than a primary cardiac event.
Thrombotic microangiopathy occurred in 11% of cases and was
characterised by thrombocytopenia, acute renal impairment and
microangiopathic haemolytic anaemia as evidenced by fragment-
ed red blood cells and anaemia. [23] An unusual association was
that thrombotic microangiopathy was just as frequent in partial
VICC compared to VICC and not associated with cardiovascular
collapse in those patients with VICC.
The study also confirmed that neurotoxicity was rare in brown
snake envenoming in humans, and only results in minor effects.
This is consistent with recent studies of brown snake venom, [24]
which showed the presynaptic neurotoxin in brown snake venom
is far less potent than that in taipan venom, and constitutes a much
smaller proportion of the venom. [24].
The study demonstrates some of the difficulties with correlating
the clinical effects in humans with the composition of the venom.
A number of studies have identified the important venom proteins
in P. textilis venom. [25,26] Some of these venom proteins play a
key role in human envenoming, such as the prothrombin activator
Pseutarin C. Pseutarin C is a potent procoagulant in vitro [27] and
is the cause of VICC seen in patients in this study. However, some
toxins identified in the venom, such as the presynaptic neurotoxin
textilotoxin, and other long and short chain post-synaptic
neurotoxins, do not appear to play an important role in human
envenoming as evidenced by the lack of neurotoxicity in the
majority of patients. The quantity and potency of the textilotoxin
explains the lack of neurotoxicity in part. [24] However, it remains
unclear why post-synaptic neurotoxins identified in the venom
[25] do not result in neurotoxicity. [28] A number of other toxins
found in P. textilis venom, such as textilinin, [25] do not appear to
play a role in human envenoming. Finally, further study is
required to determine the toxic mechanisms and specific toxins
that cause the cardiovascular effects and thrombotic microangi-
opathy, which we have shown to be characteristic of brown snake
envenoming.
The geographical distribution of brown snake envenoming was
notable with only one case in Victoria. Most brown snake bites
occurred in North-Eastern Australia and Western Australia
(Figure 2) and in these regions brown snake envenoming is likely
to be the most important cause of snake envenoming. A
comparison of three Pseudonaja groupings suggests that they are
similar clinically and produce similar venom concentrations,
which refutes previous suggestions that brown snakes from
Western Australia cause more severe envenoming or inject more
venom.
Published opinions and guidelines have offered conflicting
advice on antivenom dosing. [5,7,8,29,30] This case series
supports that the much higher doses recommended previously
are unnecessary and indeed shows that one vial of brown snake
antivenom was sufficient, with similar recovery and outcomes
compared with patients receiving larger doses. This is consistent
with recent in vitro studies showing that one vial binds all
circulating venom up to a concentration of 100 ng/ml [7] and
will neutralise the procoagulant effects. [27] In addition, no further
doses are required.
Previous recommendations of larger doses of brown snake
antivenom have been based on either the incorrect assumption
that ongoing coagulopathy is due to inadequate antivenom, [5] or
that the average venom yield used for calculating antivenom
quantities was lower than that found in more recent milking
studies. [31] However, even if brown snakes delivered 10 times the
CSL calculated average venom yield, one vial should still be
sufficient based on recent in vitro clotting studies. [7,27] Unlike
older animal work suggesting larger antivenom doses, [29,32]
these studies used venom at clinically relevant concentrations and
show neutralisation of venom concentrations measured in this
clinical study, with antivenom concentrations equivalent to dosing
with one vial. [7,27].
We were unable to determine the proportion of brown snake
bites that result in envenoming. The small proportion of non-
envenomed cases in this series was due to the fact that if venom
was not detected in blood most patients were excluded. Snake
collection and identification by an expert was uncommon.
Another limitation is the lack of routine cardiovascular investiga-
tion, including the regular collection of ECG and troponin data
that were not specifically part of the research protocol or current
clinical practice. In future it will be important for troponins and
ECGs to be done in patients following collapse.
This series confirms that VICC occurs in all brown snake
envenoming cases, and over a third of patients develop compli-
cations related to envenoming (early collapse, major haemorrhage,
thrombotic microangiopathy). The results of this study support
accumulating evidence that giving more than one vial of
antivenom is unnecessary in brown snake envenoming.
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